Drug Trial Radar · NCT06047184
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jul 15, 2019
Primary completion
Jan 30, 2024
Study completion Jan 30, 2024
Sponsor
- Lead sponsor
- BeBetter Med IncIndustry
- Sponsor type
- Industry
- Collaborators
- Hunan Cancer Hospital; Xiangya Hospital of Central South University
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study includes a dose escalation trial of BEBT-209 monotherapy in HR +/HER2- advanced breast cancer patients and a Phase 1b trial of BEBT-209 as a single therapy, in combination with letrozole, and in combination with fulvestrant in ER +/HER2- advanced breast cancer in women. To evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BEBT-209 as a single therapy, in combination with letrozole, and in combination with fulvestrant. To determine the recommended dose for late clinical studies of monotherapy or combination therapy in patients with HR +/HER2- advanced breast cancer.
Conditions
- Advanced Breast Cancer
Interventions
BEBT-209 capsulesDrug
BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
Letrozole tabletsDrug
Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
FulvestrantDrug
Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTDTime frame: 4 weeks
- DLTTime frame: 4 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hunan Cancer Hospital
Changsha, Hunan, China
Xiangya Hospital Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.